

Learner Notification

Behind the Scenes
Controversies in Dialysis Access (CiDA) 2024
October 3, 2024 – October 5, 2024
Washington, DC

Acknowledgement of Financial Commercial Support

CiDA: W.L. Gore, Healionics, Laminare Medical, Medtronic, Merit Medical, Phraxis, Sonavex, Vascular Therapies, Inc., VenoStent, Venova, Xeltis

SoDA: W.L. Gore, Laminare Medical, Merit Medical

Acknowledgement of In-Kind Commercial Support

SoDA: Abbott, Becton, Dickinson, W. L. Gore

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Behind the Scenes. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation #4008163

JOINTLY ACCREDITED PROVIDER*
INTERPROFESSIONAL CONTINUING EDUCATION

Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this live activity for a maximum of 18.75 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

- Simulation of Dialysis Access (SoDA): maximum of 4.00
- Controversies in Dialysis Access (CiDA): maximum of 14.75

American Board of Surgery (ABS) MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit. Max of 18.75 Accredited CE MOCs.

- Simulation of Dialysis Access (SoDA): maximum of 4.00
- Controversies in Dialysis Access (CiDA): maximum of 14.75

You must request your certificate within 45 days of the activity to meet the deadline for submission to PARS. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Physician Assistants

PAs may claim a maximum of 18.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

- Simulation of Dialysis Access (SoDA): maximum of 4.00

- Controversies in Dialysis Access (CiDA): maximum of 14.75

Nurse Practitioners

The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.

- Simulation of Dialysis Access (SoDA): maximum of 4.00
- Controversies in Dialysis Access (CiDA): maximum of 14.75

Objectives - After Attending This Program You Should Be Able To

- Assess ways to improve training in order to make sound clinical decisions.
- Recognize the benefits of effective communication in a multidisciplinary team setting to advance the care of dialysis patients.
- Analyze the benefits and drawbacks of different dialysis options for patients who need renal replacement.
- Identify risks and benefits of peritoneal and hemodialysis.
- Compare traditional and nontraditional approaches for arteriovenous access creation and intervention.
- Determine how best to make clinical decisions for patients with thoracic central vein obstruction.
- Identify how best to manage patients with AV fistula aneurysms.
- Discuss factors that contribute to patient safety during dialysis-access surgery and catheter-based interventions.
- Decision making in how to best treat a failing AV access.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Steven	Abramowitz	Inari Medical:Consultant,Gore:Consultant,Boston Scientific:Consultant,Philips:Consultant
Saravanan	Balamuthusamy	NA
Thiago	Barroso	Medtronic, BD, Merit, Gore, Scitech, Boston Scientific: Consultant ,BD, Merit, Scitech, Boston Scientific: Research Grant Overall Principal Investigator, Medtronic, BD, Merit, Gore, Scitech, Boston Scientific: Speakers Bureau
George	Blessios	Laminate LTD:Consultant
Deborah	Brouwer-Maier	Transonic:Employee,Medical Education Institue (non-profit):Corporate Board Member
Douglas	Cavalcanti	Merit:Consultant
Timothy	Clark	Teleflex:Patent Holder,Merit:Patent Holder,Boston Scientific:Speakers Bureau,Becton Dickinson:Consultant,Forge Medical:Stock Shareholder,Penumbra:Research Grant Site Principal Investigator
Amudha	David	NA
Dalia	Dawoud	Medtronic :Consultant
Bart	Dolmatch	becton dickinson:Research Grant Overall Principal Investigator,medtronic:Consultant,merit medical:Scientific/Medical Advisory Board Member,merit medical:Other,venovo:Private Stock Shareholder,alio:Private Stock Shareholder
Abigail	Falk	NA
Marcio	Filippo	Merit Medical Systems, Bard BD:Research Grant Site Principal Investigator,Medtronic, Boston, Bard BD, Merit Medical Systems, Scitech Medical:Consultant,Medtronic, Bard BD, Merit Medical Systems, Scitech Medical, Medcorp, :Speakers Bureau
Antonios	Gasparis	Medtronic:Scientific/Medical Advisory Board Member,BD BARD:Scientific/Medical Advisory Board Member,Boston Scientific:Scientific/Medical Advisory Board Member,Tactile:Consultant
Paul	Gibbs	Gore:Consultant
Mary	Hammes	NA
Leonardo	Harduin	NA
Ziv	Haskal	Becton Dickinson:Consultant,Becton Dickinson:Research Grant Site Principal Investigator,Boston Scientific:Consultant,Nextbiomedical:Consultant,Fluidix:Private Stock Shareholder,Sirtex:Consultant,WL Gore:Consultant
Shanika	Hewa-Geeganage	NA
Stephen	Hohmann	BD:Consultant,Gore:Consultant,Merit:Consultant,Medtronic:Consultant,Sonavex:Consultant
Karl	Illig	Merit:Other
Sriram	Iyer	Vascular Therapies, Inc.:Employee,Vascular Therapies, Inc.:Private Stock Shareholder

Ari	Kramer	Medtronic:Consultant,Sonavex:Scientific/Medical Advisory Board Member,Mozarc :Consultant,Venostent:Consultant
Nicos	Labropoulos	Boston Scientific:Consultant,Philips:Consultant,Sun Scientific:Consultant,BD BARD:Consultant
Robert	Lee	NA
Terry	Litchfield	Medtronic:Scientific/Medical Advisory Board Member,Sonavex:Scientific/Medical Advisory Board Member,Alio:Other,VentureMed:Other,Mozarc:Consultant
Charmaine	Lok	BD, Baxter, Gore, KiteLock, Medtronics:Research Grant Site Principal Investigator
Mark	London	NA
John	Lucas III	Laminate:Research Grant Site Principal Investigator
Neghae	Mawla	Pathfinder:Consultant,Venova:Consultant
Barbara	Moreira	NA
Nicholas	Morrissey	NA
Sandeep Raj	Pandey	NA
Nisarg Sunilkumar	Parekh	NA
Eric	Peden	Humacyte:Other,Venostent, Voyager:Consultant
Shaker	Qaqish	BD:Consultant
Karthik	Ramani	BD:Speakers Bureau,Sonavex :Scientific/Medical Advisory Board Member,Medtronic:Speakers Bureau
Rishi	Razdan	Medtronic:Consultant
Tracey	Reid	NA
John	Ross	NA
Shuvo	Roy	Silicon Kidney:Other,Vitara Biomedical:Scientific/Medical Advisory Board Member
Theodore	Saad	NA
Adrian	Sequeira	NA
Robert	Shahverdyan	BD/Bard:Consultant,Xeltis:Consultant,Medtronic:Consultant,Laminate medical:Consultant,Venova medical:Scientific/Medical Advisory Board Member,VentureMed:Consultant,W.L.Gore :Speakers Bureau,BrosMed Vascular:Speakers Bureau,Cardionovum:Speakers Bureau
Mohamed	Sheta	NA
Jo	Shultz	NA
Michael	Tal	Medtronic:Patent Holder,BD:Patent Holder
Scott	Trerotola	Cook Medical:Consultant,BD:Consultant,MedComp:Consultant
Himanshu	Verma	NA
Monnie	Wasse	vascudyne:Scientific/Medical Advisory Board Member,medtronic:Research Grant Overall Principal Investigator,envVeno:Other,VenoStent:Consultant,medtronic:Consultant
Alexander	Yevzlin	Sonavex:Consultant,Phraxis:Consultant

Thursday, October 3, 2024

8:10 am - 8:30 am	0.25	Keyonte: "Translating Greek to Latin: A Recipe for Success from Bench to Bedside"
8:30 am - 10:00 am	1.50	Session I: The end of Hemodialysis?
10:30 am - 12:00 pm	1.50	Session II: HAIDI and Hand Dysfunction
1:30 pm - 3:00 pm	1.50	Session III: Dialysis Around the World - The Good, the Bad and the Ugly
3:30 pm - 5:30 pm	2.00	SoDA

Friday, October 4, 2024

8:00 am - 8:30 am	0.50	"Whatever happened?" Follow-up from Cases Presented Last Year
8:30 am - 10:00 am	1.50	Session IV: The High Flow Access
10:30 am - 12:00 pm	1.50	Session V: The Basics of Access - Focus on Our Fellows
1:30 pm - 2:15 pm	0.75	Session VI: Stump the Experts
2:15 pm - 3:00 pm	0.75	"It's Academic Access" - Jeopardy 2024!
3:30 pm - 5:30 pm	2.00	SoDA

Saturday, October 5, 2024

8:00 am - 10:00 am	2.00	Session VII: New Methods, Early Results, Clinical Trials, and Innovation
10:30 am - 12:00 pm	1.50	Session VIII: Dialysis Access in Community Practice - Better Than in the University?
1:30 pm - 3:00 pm	1.50	Session IX: How to stay out of jail